TY  - JOUR
T1  - Formulation, optimization and evaluation of pellets  loaded glipizide co amorphous mixture using central  composite design to enhance solubility
AU  - Pathan, İnayat
AU  - Chishti, Nahid Anjum
AU  - Dehghan, Mohamed Hassan
PY  - 2025
DA  - July
Y2  - 2024
JF  - Journal of Research in Pharmacy
JO  - J. Res. Pharm.
PB  - Marmara University
WT  - DergiPark
SN  - 2630-6344
SP  - 1536
EP  - 1549
VL  - 28
IS  - 5
LA  - en
AB  - The objective of this study was to prepare a co-amorphous blend of BCS class II drug, glipizide (GPZ), using arginine (ARG) as co former. The co-amorphous GPZ-ARG mixtures (molar ratios 1:1, 1:2 and 2:1) were prepared by mechanical activation (ball milling) with different milling times. The obtained mixtures were characterized with respect to their thermal properties, possible molecular interactions, dissolution properties and physical stability and compared to the behaviour of pure crystalline form. Solid-state characterization of mixture revealed amorphization of GPZ after 90 min. of ball milling. GPZ-ARG co amorphous mixture (1:2) upon ball milling for 90 min. exhibited maximum solubility (3876.8 μg/ml) compared to pure drug (300.89 μg/ml). The resulting best co amorphous blend was incorporated into pellets which were prepared by extrusion spheronisation technique. The parameters related to process of pelletisation and product related parameters were optimized by using 4-factor, 5-level Central Composite Design. The pellets containing co amorphous blend, prepared by using optimal parameter settings, showed 95.67% Drug Release in 120 min. (F23). The co-amorphous mixture and the optimized formulation were found to be stable when subjected to stability study as per ICH guideline. It was concluded that co amorphous is a promising approach to overcome the solubility constraint of Glipizide which would be helpful in better management of the disease.
KW  - Glipizide
KW  - Co-amorphous
KW  - Central Composite Design
KW  - ball milling
KW  - pellets
CR  - [1] Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1. https://doi.org/10.1021/js9601896
CR  - [2] Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: Molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst. 2004;21(3):133–193. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v21.i3.10
CR  - [3] Zhang GGZ, Law D, Schmitt EA, Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev. 2004;56(3):371–390. https://doi.org/10.1016/j.addr.2003.10.009
CR  - [4] Jensen KT, Löbmann K, Rades T, Grohganz H. Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid, Proline. Pharmaceutics. 2014;6(3):416–435. https://doi.org/10.3390/pharmaceutics6030416
CR  - [5] Löbmann K, Laitinen R, Grohganz H, Gordon KC, Strachan C, Rades T. Coamorphous drug systems: Enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm. 2011;8(5):1919–1928. https://doi.org/10.1021/mp2002973
CR  - [6] Löbmann K, Strachan C, Grohganz H, Rades T, Korhonen O, Laitinen R. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm. 2012;81(1):159–169. https://doi.org/10.1016/j.ejpb.2012.02.004
CR  - [7] Qian S, Heng W, Wei Y, Zhang J, Gao Y. Coamorphous lurasidone hydrochloride-saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with ph-independent solubility behavior. Cryst Growth Des. 2015;15(6):2920–2928. https://doi.org/10.1021/acs.cgd.5b00349
CR  - [8] Hatwar P, Pathan IB, Chishti NAH, Ambekar W. Pellets containing quercetin amino acid co-amorphous mixture for the treatment of pain: Formulation, optimization, in-vitro and in-vivo study. J Drug Deliv Sci Technol. 2021;62:102350. https://doi.org/10.1016/j.jddst.2021.102350
CR  - [9] Singh G, Pai RS, Kusum Devi V. Optimization of pellets containing solid dispersion prepared by extrusion/spheronization using central composite design and desirability function. J Young Pharm. 2012;4(3):146–156. https://doi.org/10.4103/0975-1483.100020
CR  - [10] Schilling SU, Shah NH, Waseem Malick A, McGinity JW. Properties of melt extruded enteric matrix pellets. Eur J Pharm Biopharm. 2010;74(2):352–361. https://doi.org/10.1016/j.ejpb.2009.09.008
CR  - [11] Gotti R, Furlanetto S, Andrisano V, Cavrini V, Pinzauti S. Design of experiments for enantioresolution of salbutamol using dermatan sulfate in capillary electrophoresis. J Pharm Belg. 1998;53(3):190. https://doi.org/10.1016/s00219673(99)01303-5
CR  - [12] Rahim H, Sadiq A, Ullah R, Bari A, Amin F, Farooq U, Ullah Jan N, Mahmood HM. Formulation of aceclofenac tablets using nanosuspension as granulating agent: An attempt to enhance dissolution rate and oral bioavailability. Int J Nanomedicine. 2020 Nov 17;15:8999-9009. https://doi.org/10.2147/IJN.S270746
CR  - [13] Dash RN, Mohammed H, Humaira T, Ramesh D. Design, optimization and evaluation of glipizide solid self nanoemulsifying drug delivery for enhanced solubility and dissolution. Saudi Pharm J. 2015;23(5):528–540. https://doi.org/10.1016/j.jsps.2015.01.024
CR  - [14] Karagianni A, Kachrimanis K, Nikolakakis I. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: Composition, preparation, characterization and formulations for oral delivery. Pharmaceutics. 2018;10(3):98. https://doi.org/10.3390/pharmaceutics10030098
CR  - [15] Korhonen O, Pajula K, Laitinen R. Rational excipient selection for co-amorphous formulations. Expert Opin Drug Deliv. 2017;14(4):551-569. https://doi.org/10.1080/17425247.2016.1198770
CR  - [16] Heinz A, Strachan CJ, Gordon KC, Rades T. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol. 2009;61(8):971–988. https://doi.org/10.1211/jpp/61.08.0001
CR  - [17] Zhu S, Gao H, Babu S, Garad S. Co-amorphous formation of high-dose zwitterionic compounds with amino acids to improve solubility and enable parenteral delivery. Mol Pharm. 2018;15(1):97-107. https://doi.org/10.1021/acs.molpharmaceut.7b00738
CR  - [18] Laitinen R, Löbmann K, Grohganz H, Priemel P, Strachan CJ, Rades T. Supersaturating drug delivery systems: The potential of co-amorphous drug formulations. Int J Pharm. 2017;532(1):1–12. https://doi.org/10.1016/j.ijpharm.2017.08.123
CR  - [19] Hausner HH. Friction Conditions in a Mass of Metal Powder. Int J Powder Metall. 1967;3:7–13.
CR  - [20] Hirano A, Kameda T, Arakawa T, Shiraki K. Arginine-assisted solubilization system for drug substances: Solubility experiment and simulation. J Phys Chem B. 2010;114(42):13455–13462. https://doi.org/10.1080/17425247.2016.1198770
CR  - [21] Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-1075. https://doi.org/10.1016/j.drudis.2007.09.005
CR  - [22] Kilor VA, Sapkal NP, Awari JG, Shewale BD. Development and characterization of enteric-coated immediate-release pellets of aceclofenac by extrusion/spheronization technique using κ-carrageenan as a pelletizing agent. AAPS PharmSciTech. 2010;11(1):336–343. https://doi.org/10.1208/s12249-010-9389-9
CR  - [23] Ibrahim MA, El-badry M. Formulation of immediate release pellets containing famotidine solid dispersions. Saudi Pharm J. 2014;22(2):149–156. http://dx.doi.org/10.1016/j.jsps.2013.01.011
CR  - [24] Law MFL, Deasy PB. Use of canonical and other analyses for the optimization of an extrusion-spheronization process for indomethacin. Int J Pharm. 1997;146(1):1–9. https://doi.org/10.1016/S0378-5173(96)04741-2
CR  - [25] Gowda DV, Rajesh N, Moin A, Shivakumar HG, Siddaramaiah. Controlled release behaviour of nifedipine from the pellets of gelucire/microcrystalline cellulose blends. Int J PharmTech Res. 2010;2(2):1215–1226. https://doi.org/10.1208/pt0803051
CR  - [26] Singh R, Poddar SS, Chivate A. Sintering of wax for controlling release from pellets. AAPS PharmSciTech. 2007;8(3):E175-E183. https://doi.org/10.1208/pt0803051
CR  - [27] Mandal U, K. Gowda V, Ghosh A, Senthamıl SP, Sam Solomon W, Pal T. Development of dissolution medium for glipizide. Asian J Chem. 2010;20(4):2651–2656.
CR  - [28] CPMP/ICH. ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products. Eur Med Agency. 1998;(January):1–14.
CR  - [29] Pathan IB, Munde SJ, Shelke S, Ambekar W, Mallikarjuna Setty C. Curcumin loaded fish scale collagen-HPMC nanogel for wound healing application: Ex-vivo and In-vivo evaluation. Int J Polym Mater Polym Biomater. 2019;68(4):165–174. https://doi.org/10.1080/00914037.2018.1429437
UR  - https://dergipark.org.tr/en/pub/jrespharm/issue//1690569
L1  - https://dergipark.org.tr/en/download/article-file/4833436
ER  -